Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China
Shots:
- The company has initiated a P-III ESLIM-01 trial to evaluate the efficacy and safety of HMPL-523 in 180 adult patients with ITP. The study is based on the results of the P-Ib study in patients with the same indication
- The 1EPs of the study is the DRR. The 2EPs and exploratory EPs include ORR, the incidence of treatment-emergent AEs, and patient QoL improvement
- Additionally, the company currently obtains all rights to HMPL-523 globally & the therapy is being evaluated in indolent NHL and multiple subtypes of B-cell malignancies in the US, China, US & EU. The company also plans to assess the therapy for patients with the wAIHA & other autoimmune disorder
| Ref: Hutchmed | Image: Globe Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com